RLS: Restless Legs syndrome.. Other specified extrapyramidal and movement disorders
Conditions
Interventions
Intervention 1: capsules of gabapentin 200 mg after evry hemodialysis for 4wks 2hours befor sleep. Intervention 2: tablet levodopa -c 110mg nightly 2 hours befor sleep for 4 wks.
Treatment - Drugs
capsules of gabapentin 200 mg after evry hemodialysis for 4wks 2hours befor sleep
tablet levodopa -c 110mg nightly 2 hours befor sleep for 4 wks
Sponsors
Sponsor name 1 Vice-chancellor of Research and Technology of Kermanshah University of Medical
Eligibility
Sex/Gender
All
Age
15 Years to 100 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria :minimal time of hemodialysis : 3 mount ?IRLSSG scale more than 10? Patient`s age more than 15 years Exclusion criteria: Under treatment with psychotropic agents during recent 2 weeks?presence of another neurologic disease comorbid with ESRD for example CVA, MS and etc.?Iron deficiency anemia?Pregnancy
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of RLS. Timepoint: At first &4 wks after first drug administration before second drug administration & 4 wks after second drug administration (end of the study). Method of measurement: with IRLSSG scale.;Severity of sleep disorder. Timepoint: At first &4 wks after first drug administration before second drug administration & 4 wks after second drug administration (end of the study). Method of measurement: with pittsburg sleep quality index.;Quality of life. Timepoint: At first &4 wks after first drug administration before second drug administration & 4 wks after second drug administration (end of the study). Method of measurement: with SF-36 (scale of quality of life).;Day time sleepiness. Timepoint: At first &4 wks after first drug administration before second drug administration & 4 wks after second drug administration (end of the study). Method of measurement: Epworth sleepiness scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Drug advers reaction. Timepoint: At first &4 wks after first drug administration before second drug administration & 4 wks after second drug administration (end of the study). Method of measurement: with question from patients. | — |
Countries
Iran (Islamic Republic of)
Outcome results
None listed